Nucleus accumbens-associated protein 1 (NACC1) (NACC1)

Nucleus accumbens-associated protein 1 (NACC1) is a member of the BTB/POZ domain-containing protein family that functions primarily as a transcriptional repressor and a molecular scaffold [1][2]. While initially discovered for its role in the brain's reward circuitry in response to drugs of abuse, NACC1 has emerged as a significant oncogene overexpressed in several malignancies, including ovarian, cervical, and breast cancers [3][4]. It contributes to tumor progression by promoting cell survival, inhibiting apoptosis, and maintaining a stem-like phenotype in cancer cells [2][5]. Crucially, NACC1 is a key mediator of chemoresistance, particularly to taxanes like paclitaxel, by modulating DNA damage response pathways and interacting with proteins like HDAC6 [4][6]. Therapeutic strategies targeting NACC1 mRNA, such as siRNA or antisense oligonucleotides, aim to downregulate its expression to restore drug sensitivity and inhibit tumor growth [7]. Additionally, its involvement in neuropsychiatric conditions like cocaine addiction suggests that modulating its activity could have implications beyond oncology, though this also raises concerns regarding potential neurological side effects [8].

Other names

NAC1BTBD14BBEND8Nucleus accumbens-associated protein 1BTB domain-containing protein 14B

RNA interference (siRNA) or antisense oligonucleotides (ASO) to induce mRNA degradation and reduce protein expression; small molecule inhibition of the BTB domain to prevent dimerization and transcriptional activity [1][7].